genprowebdirectory
Facebook Linkedin RSS Twitter Youtube
  • GEN Edge
    • Featured News
    • Multimedia
  • News
    • Insights
  • Topics
    • Artificial Intelligence
    • Bioprocessing
    • Cancer
    • Drug Discovery
    • Genome Editing
    • Infectious Diseases
    • OMICs
    • Translational Medicine
  • Magazine
    • Browse Issues
    • Subscribe
  • Multimedia
    • Summits
    • Webinars
    • GEN Live
    • Learning Labs
    • Podcasts
  • Resources
    • eBooks/Perspectives
    • Tutorials
    • Peer-Reviewed Journals
      • GEN Biotechnology
      • Re:Gen Open
    • New Products
    • Conference Calendar
  • Subscribe
    • Get GEN Magazine
    • Get GEN eNewsletters
Search
Facebook Linkedin RSS Twitter Youtube
Sign in
Welcome! Log into your account
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
A password will be e-mailed to you.
Genetic Engineering & Biotechnology News GEN – Genetic Engineering and Biotechnology News
Genetic Engineering & Biotechnology News Genetic Engineering & Biotechnology News
  • GEN Edge
    • Featured News
    • Multimedia
  • News
    • Insights
  • Topics
    • Artificial Intelligence
    • Bioprocessing
    • Cancer
    • Drug Discovery
    • Genome Editing
    • Infectious Diseases
    • OMICs
    • Translational Medicine
  • Magazine
    • Browse Issues
    • Subscribe
  • Multimedia
    • Summits
    • Webinars
    • GEN Live
    • Learning Labs
    • Podcasts
  • Resources
    • eBooks/Perspectives
    • Tutorials
    • Peer-Reviewed Journals
      • GEN Biotechnology
      • Re:Gen Open
    • New Products
    • Conference Calendar
  • Subscribe
    • Get GEN Magazine
    • Get GEN eNewsletters
Home 2023

Inovio Pharmaceuticals

At ESGCT, Precigen Data Supports Its Lead Candidate as RRP Treatment
Drug Discovery

At ESGCT, Precigen Data Supports Its Lead Candidate as RRP Treatment

EC Okays Merck Serono’s Rebif for Patients With Early Stages of MS
News

EC Okays Merck Serono’s Rebif for Patients With Early Stages of MS

Late-Stage Study Results Show Dynavax’ HBV Vaccine Is Better at Protecting Diabetics than Engerix-B
Drug Discovery

Late-Stage Study Results Show Dynavax’ HBV Vaccine Is Better at Protecting Diabetics than Engerix-B

PregLem Reports Phase III Success for Uterine Fibroids Therapy
News

PregLem Reports Phase III Success for Uterine Fibroids Therapy

Read the Digital Edition

August 2023 cover

Explore

  • About GEN
  • Contact GEN
  • GEN Staff
  • Editorial Guidelines
  • Reprints and Permissions
  • Scientific Advisory Board

Advertise

  • Media Kit and Planning Calendar
  • Advertising Terms and Conditions

Resources

  • Get the GEN Magazine
  • Get the GEN Email Newsletter
  • Inside Precision Medicine
  • Privacy Policy
Copyright © 2023 Genetic Engineering & Biotechnology News. All Rights Reserved.
Scroll Up